Managing Toxicities Associated With CAR T-Cell Therapy

Download this slideset for expert perspectives on best practices and key knowledge for nurses in the management of key adverse events associated with CAR T-cell therapy.
person default
Kathleen McDermott, RN, BSN, OCN, BMTCN
Format: Microsoft PowerPoint (.ppt)
File Size: 826 KB
Released: May 19, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Celgene Corporation

Related Content

Expert slides on biologic principles, indications, and clinical biomarkers for immune checkpoint inhibitors, from Clinical Care Options (CCO)

Sandip P. Patel, MD Released: April 16, 2021

Expert slides on multidisciplinary management of immune-related adverse events associated with checkpoint inhibitors, from Clinical Care Options (CCO)

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP Released: April 16, 2021

Clinical Care Options (CCO) on-demand video featuring expert perspectives on using cytokine therapy for melanoma

Ahmad Tarhini, MD, PhD
Program Director
person default George Ebanks, RN, BSN, OCN person default Jennifer Swank, PharmD, BCOP
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 8, 2021 Expired: April 7, 2022

Quickly access expert treatment recommendations for patients with advanced head and neck cancer with this decision tool.

Barbara Burtness, MD
Program Director
Robert L. Ferris, MD, PhD person default Ranee Mehra, MD Cristina P. Rodriguez, MD Jared Weiss, MD
Released: April 6, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue